Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest ArticlesSorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2
Hepatology, 10/13/09
Blechacz BRA et al. – Sorafenib accelerates STAT3 dephosphorylation by stimulating phosphatase SHP2 activity, sensitizes CCA cells to TRAIL–mediated apoptosis, and is therapeutic in a syngeneic, orthotopic CCA model that mimics human disease.
Today in GI Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Treatment of Fistulizing Inflammatory Bowel Disease
Gastroenterology Clinics of North America, 11/13/09
Safety Profile of IBD: Lymphoma Risks
Gastroenterology Clinics of North America, 11/16/09
Image-enhanced endoscopy in practice
Canadian Journal of Gastroenterology, 11/06/09
Today in Hepatology...keeping you current
Receive free subspecialty "5-minute updates" via email
Liver disease: Early signs you may be missing
APCToday, 10/21/09
Non-alcoholic fatty liver disease from pathogenesis to management: an update
Obesity Reviews, 11/02/09
Severe sepsis in cirrhosis
Hepatology, 11/04/09
Sponsor
Article Search
Sponsor